Abstract
In this issue of Blood, Pabst et al report that granulocyte-colony stimulating factor (G-CSF) "priming" improves event-free and overall survival (EFS and OS) only in those adults less than 60 years old given escalated doses of cytarabine (ara-C) for treatment of newly diagnosed acute myeloid leukemia (AML).
Cite
CITATION STYLE
APA
Estey, E. (2012, June 7). Be quick, but don’t hurry. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2012-04-418574
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free